GoodRx Holdings Stock News

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., today announced it is working with ARS Pharmaceuticals, Inc. (“ARS Pharmaceuticals”) to offer the lowest discounted cash price for neffy® in retail pharmacy locations. Available for purchase in-store this week, consumers who have been prescribed neffy can now access a pack of two...

NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against GoodRx Holdings, Inc. (NASDAQ: GDRX) on behalf of long-term stockholders following a class action complaint that was filed against GoodRx on April 22, 2024 with a Class Period from September 23, 2020, to November 8, 2022. Our in...

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading prescription savings platform in the U.S., today announced that executives from the Company will participate in a fireside chat at each of the following investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY on Thursday, September 5, 2024 at...

It was a mixed bag of growth and challenges for digital healthcare platform GoodRx during the second quarter. In reporting its second-quarter results Thursday (Aug. 8), GoodRx said monthly active users (MACs) rose 8%, contributing to a 7% rise in prescription transactions revenue, which totaled $146.7 million.

GoodRx Holdings, Inc. (NASDAQ:GDRX ) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Aubrey Reynolds - Director of Investor Relations Scott Wagner - Interim Chief Executive Officer Karsten Voermann - Chief Financial Officer Mike Walsh - President & EVP, Prescription Marketplace Conference Call Participants Charles Rhyee - TD Cowen Lisa Gill - JPMorgan John Ransom...

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading prescription savings platform in the U.S., has released its financial results for the second quarter of 2024. Second Quarter 2024 Highlights Revenue1 and Adjusted Revenue1 of $200.6 million Net income of $6.7 million; Net income margin of 3.3% Adjusted Net Inc...

GoodRx stock rated a sell due to industry headwinds, cost growth outpacing revenue, and needing 12%+ growth to justify price. Q2 earnings expected to be in line with guidance, but long-term guidance doesn't support current price point. Upside potential if GoodRx doubles market growth, but industry headwinds and growth struggles pose challenges.

A close copy version of Abbvie's blockbuster arthritis drug Humira will be available at a 92% discount to its list price on the GoodRx website, the digital healthcare platform and German drugmaker Boehringer Ingelheim said on Thursday.